Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)

RB Warren; A Blauvelt; J Bagel; KA Papp; P Yamauchi; A Armstrong; R Langley; V Vanvoorden; D De Cuyper; L Peterson; N Cross; K Reich

doi:10.25251/skin.5.supp.15

RB Warren

Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK

A Blauvelt

Oregon Medical Research Center, Portland, OR, USA

J Bagel

Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, USA

KA Papp

Probity Medical Research and K Papp Clinical Research, Waterloo, Ontario, Canada

P Yamauchi

Dermatology Institute and Skin Care Center, Santa Monica, CA, USA; Division of Dermatology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA

A Armstrong

Keck School of Medicine of USC, Dermatology, Los Angeles, CA, USA

R Langley

Dalhousie University, Halifax, Nova Scotia, Canada

V Vanvoorden

UCB Pharma, Brussels, Belgium

D De Cuyper

UCB Pharma, Brussels, Belgium

L Peterson

UCB Pharma, Raleigh, NC, USA

N Cross

UCB Pharma, Raleigh, NC, USA

K Reich

Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf and Skinflammation? Center, Hamburg, Germany

Keywords

Plaque Psoriasis, Bimekizumab, IL-17A, IL-17F, Adalimumab, Biologic, Efficacy, Safety

Abstract

Abstract not available.

References

1. Durham L. Curr Rheumatol Reports 2015;17:55

2. Fujishima S. Arch Dermatol Res 2010;302:499–505

3. Glatt S. Br J Clin Pharmacol 2017;83:991–1001

4. Papp KA. J Am Acad Dermatol 2018;79:277–86.e10

5. Reich K. AAD 2020, NCT03370133

6. Gordon K. AAD 2020, NCT03410992.

Poster PDF

Published

Jan 1, 2021

DOI https://doi.org/10.25251/skin.5.supp.15

How to Cite

[1]

Warren, R., Blauvelt, A., Bagel, J., Papp, K., Yamauchi, P., Armstrong, A., Langley, R., Vanvoorden, V., De Cuyper, D., Peterson, L., Cross, N. and Reich, K. 2021. Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE). SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s15. DOI:https://doi.org/10.25251/skin.5.supp.15.

Issue

Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)

Section

Poster Presentations from FC23 Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

KA Papp, M Lebwohl, AB Gottlieb, M Sebastian, R Langley, Y Okubo, M Wang, C Cioffi, F Staelens, K Reich, Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis with Scalp, Nail and Palmoplantar Involvement Through 52 Weeks: Post-Hoc Analysis from the BE VIVID Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
RB Warren, C Conrad, P Foley, L Iversen, RG Langley, G Kokolakis, L Davis, V Vanvoorden, S Wiegratz, JF Merola, Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
K Reich, K Papp, A Blauvelt, R Langley, A Armstrong, RB Warren, K Gordon, JF Merola, C Madden, M Wang, V Vanvoorden, M Lebwohl, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
C.E.M. Griffiths, K.A. Papp, M Song, M Miller, Y You, Y-K Shen, C Han, A Blauvelt, Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
K Reich, A Blauvelt, M Lebwohl, KA Papp, P Rich, B Strober, D De Cuyper, C Madden, L Peterson, V Vanvoorden, RB Warren, Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
PCM van de Kerkhof, K Reich, CL Leonardi, A Blauvelt, NN Mehta, TF Tsai, R You, P Papanastasiou, M Milutinovic, CEM Griffiths, Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
CEM Griffiths, KA Papp, M Song, B Randazzo, S Li, YK Shen, C Han, A Blauvelt, Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 2 (2018): Supplemental Issue: Scientific Posters & Abstracts Presented at 2018 Fall Clinical Dermatology Conference®-Las Vegas
K Gordon, P Foley, JG Krueger, A Pinter, K Reich, R Vender, V Vanvoorden, C Madden, L Peterson, A Blauvelt, Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
K Gordon, P Foley, P Rich, K Duffin, A Pinter, CEM Griffiths, M Wang, V Vanvoorden, F Staelens, V Ciaravino, JF Merola, Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 1 (2021): January Issue & Poster Presentations (WC21 Dermatology Conference®)
A Blauvelt, KC Duffin, N Magnolo, J Weisman, M Ståhle, D Wilsmann-Theis, M Wang, K Wixted, B Szilagyi, L Puig, Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

1 2 3 4 5 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Similar Articles

Most read articles by the same author(s)